StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report report published on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.59 on Monday. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75. The company has a market cap of $267.55 million, a P/E ratio of -57.38 and a beta of 0.77. The stock’s fifty day moving average price is $5.21 and its 200-day moving average price is $5.17.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The firm had revenue of $50.47 million during the quarter. As a group, analysts expect that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. SageView Advisory Group LLC purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $34,000. Meeder Asset Management Inc. bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $39,000. China Universal Asset Management Co. Ltd. grew its holdings in Vanda Pharmaceuticals by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 4,387 shares in the last quarter. SG Americas Securities LLC bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.